The General Fund is dedicated to supporting the Sound Affects day to day operation. By supporting our operation, you can help us better serve our cancer-fighting campaigns through the crowdfunding process from start to finish. The General Fund is also used to match donations made to our other fundraising campaigns.
Sound Affects is entirely focused on transforming the fight against cancer from current stagnation to success by working with musicians. Our objective is to raise the visibility of biotech entrepreneurs developing innovative clinical solutions for cancer, and to generate funds to help advance these technologies through the product development pipeline.
You can support Sound Affects directly by contributing to our General Fund. The General Fund is dedicated to supporting the Sound Affects day to day operation. By supporting our operation, you can help us better serve our cancer-fighting campaigns through the crowdfunding process from start to finish.
The General Fund is also used to match donations made to our other fundraising campaigns.
Mona is the founder, executive director, and chairman of the board at Sound Affects. She launched Sound Affects to address the “Valley of Death,” the growing gap in funding that constrains the translation of cancer research discoveries into clinical applications.
Claire Schultz is an award-winning strategist with three decades of executive level management experience at Hearing Health Foundation, Amnesty International, Juvenile Diabetes Research Foundation (JDRF), NBC, Microsoft, and Disney/ABC, Inc.
Leonardo Cavalli, an award winning business expert, is skilled at teaching the art of negotiation. He is also a New York based motivational speaker that travels the world helping individuals get the most out of their lives.
Dr. Maguire is a company founder, member of the Board of Directors, and currently President and Chief Executive Officer of VascuLogic LLC, and a managing partner of Vicara Capital.
As cancer affects millions of Americans each year, national efforts to cure this disease have largely focused on cancer research rather than cancer product development. SoundAffects believes that the key to bridging the Valley of Death is:
Prior to SoundAffects, our founder (Mona Jhaveri) founded Foligo Therapeutics, Inc. in 2005 to develop and commercialize a DNA-based therapeutic compound as a potential treatment for ovarian cancer. While Foligo was able to initially attract funding from various state-run venture programs and business plan competitions, the company ultimately succumbed to the Valley of Death.
In 2010, Foligo closed its laboratory and research facilities due to a funding drought. While there is no guarantee that Foligo’s targeted therapies for ovarian cancer would have worked, there was enough evidence and promise in early proof-of-principle studies to continue the work.
Mona realized that breaking this funding bottleneck was a more critical priority than Foligo and rededicated herself to Sound Affects and its mission.